← 返回专利悬崖列表
CAS 2730017-96-4
(4S,5S)-4-[(1S,6S)-6-(Benzyloxy)-2-bromo-1,3-dimethylcyclohex-2-en-1-yl]-2,2-dimethyl-5-(6,6,8-trimethyl-1,4-dithiaspiro[4.5]dec-7-en-7-yl)-1,3-dioxolane
登记编号：(IX)101438-71-a
应用背景（按来源药适应症）
乳腺癌Paclitaxel/Encequidar mesylate腺癌Paclitaxel/Encequidar mesylate血管肉瘤Paclitaxel/Encequidar mesylate实体瘤Paclitaxel/Encequidar mesylate
来源药（使用该中间体的合成路线）
| 品种 | 梯队 | 到期年 |
|---|---|---|
| Paclitaxel/Encequidar mesylatePaclitaxel/Encequidar mesylate | Tier C · 观察 / 贸易 | - |
合成路线中的位置（上下游链）
按路线登记顺序排列，左→右为合成方向；高亮为当前 CAS，其余可点击跳转对应档案。
(2R,3S)-3-Hydroxy-2-methyl-2-(prop-2-en-1-yl)cyclohexan-1-one→(2R,3S)-3-(Benzyloxy)-2-methyl-2-(prop-2-en-1-yl)cyclohexan-1-one→[(3R,4S)-4-(Benzyloxy)-2-bromo-3-methyl-3-(prop-2-en-1-yl)cyclohex-1-en-1-yl]methanol→([[(1S,2R)-3-Bromo-2,4-dimethyl-2-(prop-2-en-1-yl)cyclohex-3-en-1-yl]oxy]methyl)benzene→(4S,5S)-4-[(1S,6S)-6-(Benzyloxy)-2-bromo-1,3-dimethylcyclohex-2-en-1-yl]-2,2-dimethyl-5-(6,6,8-trimethyl-1,4-dithiaspiro[4.5]dec-7-en-7-yl)-1,3-dioxolane→[(1R,6S)-6-(Benzyloxy)-2-bromo-1,3-dimethylcyclohex-2-en-1-yl]acetaldehyde→([2-[(1R,6S)-6-(Benzyloxy)-2-bromo-1,3-dimethylcyclohex-2-en-1-yl]ethenyl]oxy)(tert-butyl)dimethylsilane→(2S)-[(1S,6S)-6-(Benzyloxy)-2-bromo-1,3-dimethylcyclohex-2-en-1-yl][(2-methoxypropan-2-yl)oxy]acetaldehyde→7-Iodo-6,6,8-trimethyl-1,4-dithiaspiro[4.5]dec-7-ene→(5S,6S)-5-(Benzyloxy)-6-[(4S,5S)-2,2-dimethyl-5-(6,6,8-trimethyl-1,4-dithiaspiro[4.5]dec-7-en-7-yl)-1,3-dioxolan-4-yl]-2,6-dimethylcyclohex-1-ene-1-carbaldehyde→(5S,6S)-5-(Benzyloxy)-6-[(4S,5S)-2,2-dimethyl-5-(2,6,6-trimethyl-5-oxocyclohex-1-en-1-yl)-1,3-dioxolan-4-yl]-2,6-dimethylcyclohex-1-ene-1-carbaldehyde→(3aS,8S,9S,13S,13aS,13bS)-13-(Benzyloxy)-2,2,5,10,13a,14,14-heptamethyl-6,7,9,11,12,13,13a,13b-octahydro-2H-4,8-methanobenzo[3,4]cyclodeca[1,2-d][1,3]dioxole-8,9(3aH)-diol→(1S,5S,10S,11S,12S,16S)-10-(Benzyloxy)-7,11,14,14,18,21,21-heptamethyl-2,4,13,15-tetraoxapentacyclo[15.3.1.0(1,5).0(6,11).0(12,16)]henicosa-6,17-dien-3-one
本站可供应的对应中间体
目录暂未收录该靶点的在售中间体 —— 可直接发起询价，需求会进入撮合池。
本页为中间体 CAS 注册档案：同 CAS 的多条路线登记已合并；后续供应商报价与买方需求以该 CAS 为主键撮合。